3''-desmethoxy derivatives of erythromycin and azithromycin
CA 2184734 C · Owner: Pfizer Inc. · Inventors: Yang, Bingwei V.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound having for-, mula (IV), wherein Z is CH2- N(CH3), N(CH3)-CH2, or (a); R1, and R2 are selected from 1) one of R1 and R2 is OH and the other, of R1 and R2 is (C1-C6)alkyl (C2-, C6)alkenyl, or phenyl, with the, proviso that Z is not CO; 2) one of R1 and R2 is H and the other, of R1 and R2 is NR5R6 wherein, R5 and R6 are independently selected from H and (C1-C6)alkyl, or is OR7 wherein R7 is H or, (C1-C6)alkyl; and 3) R1 and R2 together form an oxo or oxime group; R3 and R4 are each hydroxyl or together form a carbonate or thiocarbonate group; and pharmaceutically acceptable salts thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 2, 1995 and granted August 3, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 2, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 2, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.